Researchers at the University of California, Davis have developed a method to treat liver and colon cancer using natural or synthetic retinoids in combination with histone deacetylase inhibitors.
The incidence of liver and colon cancer is rising due to obesity and metabolic syndrome. It has been found that the gut microenvironment is altered due to unhealthy diet in animals with dysbiosis, lack of nutrients, and dysregulated bile acid synthesis. Despite this correlation, most treatments for liver and colon cancer (such as a colectomy or chemotherapy) do not attempt to address the alteration of the gut microenvironment as a form of recovery.
Researchers at the University of California, Davis have developed a method to treat colon and liver cancer by using retinoids and histone deacetylase inhibitors (HDAC inhibitors) using both natural compounds and synthetic chemicals. In addition, the researchers have uncovered novel mechanism for such anti-cancer effects. Retinoids and HDAC inhibitors can work through specific microRNAs (which are tumor suppressive) to induce apoptosis and arrest of liver and colon cancer cells. Additionally, they reduce inflammation and improve metabolism. The treatment has been successfully tested in vitro in human colon and liver cancer cells, ex vivo in human colon and liver biopsies and in vivo in specific knockout mice as well as xenograt tumor models.
|United States Of America||Issued Patent||2019-03077||10/10/2019||2016-363|
|Patent Cooperation Treaty||Published Application||2018089861||05/17/2018||2016-363|
retinoids, histone deacetylase inhibitors, HDAC inhibitors, colon cancer, liver cancer, protein deacetylase, tumor suppressors, microRNAs, gut-liver axis, gut microbiota, type 2 diabetic mellitus, metabolism, inflammation